Politician trade (House)

AbbVie (ABBV): Rep. Julia Letlow (LA05) disclosed a sale $1K–$15K

Rep. Julia Letlow (LA05) disclosed a sale of AbbVie in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
36 days
Disclosure lag
Traded
Dec 8, 2025
Disclosed
Jan 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2024CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  2. Jan 24, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  3. Apr 28, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  4. Oct 10, 2025FDAFDA drug approval: Rinvoq
  5. Oct 30, 2025Federal contract · $21K obligatedDepartment of Defense awarded AbbVie: $21K obligated to date
  6. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  7. Oct 31, 2025Company filing · Form 8-K · ResultsReported its results
  8. Oct 31, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  9. Nov 4, 2025FDAFDA drug approval: Linzess
  10. Nov 10, 2025Layoff notice · 5996 Gleason Drive Dublin CA 94568Layoff notice filed in CA: 48 employees
  11. Nov 10, 2025Layoff notice · 7041 Las Positas Road Livermore CA 94551Layoff notice filed in CA: 9 employees
  12. Nov 10, 2025Layoff notice · 4410 Rosewood Drive Pleasonton CA 94588Layoff notice filed in CA: 2 employees
  13. Nov 13, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  14. Dec 8, 2025 · this disclosureCongressDisclosed sale of ABBV — reported range $1,001 - $15,000

What came next

  1. Dec 8, 2025Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $3.8K obligated to date
  2. Dec 12, 2025Federal contract · $24K obligatedDepartment of Defense awarded AbbVie: $24K obligated to date
  3. Dec 18, 2025FDAFDA drug approval: Vraylar
  4. Dec 18, 2025FDAFDA drug approval: Vraylar
  5. Dec 18, 2025FDAFDA drug approval: Vraylar
  6. Dec 18, 2025FDAFDA drug approval: Vraylar
  7. Dec 18, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  8. Dec 22, 2025Government · Federal Register noticeCertain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Institution of Investigation
  9. Jan 7, 2026Company filing · Form 8-K · ResultsReported its results
  10. Jan 16, 2026FDAFDA device clearance: Natrelle 133S Tissue Expanders
  11. Jan 20, 2026Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $4K obligated to date
  12. Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
  13. Feb 19, 2026FDAFDA drug approval: Venclexta
  14. Feb 25, 2026Insider · Their largest sale since 2023Officer sold ~$5.15M of ABBV shares in the open market
  15. Mar 2, 2026Insider · 1 personInsiders: 3 sales (~$4.4M)
  16. Mar 4, 2026InsiderOfficer sold ~$1.22M of ABBV shares in the open market
  17. Mar 6, 2026FDAFDA drug approval: Skyrizi
  18. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
  19. Mar 9, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  20. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for AbbVie

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

Other recent filings by Rep. Julia Letlow (LA05)

The full history of Rep. Julia Letlow (LA05) is on the profile page.

How this filing works

Explore the data

Common questions

Which member of Congress traded AbbVie (ABBV) stock, and how much?

Rep. Julia Letlow (LA05) disclosed a sale of AbbVie in the $1K–$15K range. Reported range, not an exact amount.

When did it happen, and when was it made public?

Traded: Dec 8, 2025. Disclosed: Jan 13, 2026. That is 36 days between the two dates.

Why is the amount a range and not an exact figure?

Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.

Where does this information come from?

From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about AbbVie recently?

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABBV page.

Does this mean ABBV stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at AbbVie

Everything OQRO holds on this company is on its ABBV page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data